The Exclusion of Women from Clinical Trials of Thrombolytic Therapy

Charles Maynard, Harry P. Selker, Joni R. Beshansky, John L. Griffith, Christopher H. Schmid, Robert M. Califf, Ralph B. D'Agostino, Michael M. Laks, Kerry L. Lee, Galen S. Wagner and W. Douglas Weaver

Medical Decision Making, 1995, vol. 15, issue 1, 38-43

Abstract: The thrombolytic predictive instrument (TPI) was developed to identify those patients most likely to benefit from thrombolytic therapy for acute myocardial infarction as well as to facilitate the earliest possible administration of this treatment. The TPI consists of predictive models derived from clinical data obtained from both clinical trials and data registries. These models are subject to potential bias due to combinations of primary data from different sources. The purpose of this investigation was to assess the influence of gender in developing the TPI database. In this database, there were 1,096 (22%) women and 3,826 (78%) men; only 38% of the women were enrolled in clinical trials, whereas 46% of the men were (p

Date: 1995
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X9501500107 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:15:y:1995:i:1:p:38-43

DOI: 10.1177/0272989X9501500107

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().